Thymosin alpha-1 synergizes with cytokines (IFN-alpha, IFN-gamma, IL-2, IL-12) to amplify immune responses beyond what either achieves alone — the molecular basis for its combination immunotherapy success.
Key findingThymosin alpha-1 synergizes with IFN-alpha, IFN-gamma, IL-2, and IL-12 to amplify T-cell, NK cell, and dendritic cell responses through complementary
What the researchers found
Thymosin alpha-1 synergizes with IFN-alpha, IFN-gamma, IL-2, and IL-12 to amplify T-cell, NK cell, and dendritic cell responses through complementary signaling pathways — explaining why combination therapy outperforms monotherapy for infections and cancer.
Why it matters
Relevant for thymosin-alpha-1, immune-function, cancer.
How the study worked
review study on thymosin-alpha-1, immune-function.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Immunopharmacology of thymosin alpha1 and cytokine synergy.
Annals of the New York Academy of Sciences, 1112, 235-44
Citation
Naylor, Paul H; Quadrini, Karen; Garaci, Enrico; Rasi, Guido; Hadden, John W. (2007). Immunopharmacology of thymosin alpha1 and cytokine synergy.. Annals of the New York Academy of Sciences, 1112, 235-44.